Development and validation of RP-HPLC method for simultaneous quantification of the anticancer agents, nilotinib and sorafenib: Application in In-vitro analysis
نویسندگان
Azra Takhvar, Somaye Akbari, Effat Souri, Reza Ahmadkhaniha, Ali Morsali, Mohammad Reza Khoshayand, Mohsen Amini
تاریخ انتشار
2022/1/1
ژورنال
Progress in Chemical and Biochemical Research
جلد
5
نسخه
1
صفحات
44-52
توضیح
Tyrosine kinase inhibitors (TKIs) are smallmolecules which are often used to treat a variety of malignancies. According to earlier research, TKIs may enhance the long-term survival of patients in certain instances [1]. However, in some cases, such as chronic myeloid leukemia (CML) patients, response failure to such treatment are still seen [2]. Furthermore, like other anticancer drugs, the majority of patients suffer from severe side effects [3]. Nilotinib, 4-methyl-N-3-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl) phenyl)-3-(4-(pyridine-3-yl) pyramidin-2-ylamino) benzamide (Fig. 1), a second generation tyrosine kinase inhibitor is applied to treat the imatinib-resistant chronic myelogenous leukemia. Nilotinib shows in vitro efficacy against several imatinib-resistant mutations and is selective for BCR-ABL, binding more than 20 times that of the affinity of imatinib [4-6]. Sorafenib tosylate, 4-[4-({[4-chloro-3-trifluoromethyl) phenyl] carbamoyl} amino) phenoxy]-N-methylpyridine-2-carboxamide (Fig. 2), is a multi-kinase inhibitor utilized in the colorectal cancer and hepatocellular carcinoma. As a monotherapy agent or in combination with other antitumor agents, sorafenib has indicated significant anticancer activity against different tumor types. In preclinical and clinical studies, it was proved that in addition to induction of apoptosis in tumor cells, sorafenib hinders cell proliferation as well as angiogenesis,[7-10]. Few analytical methods are available for the determination of nilotinib and sorafenib in bulk and pharmaceutical dosage forms [11-18]. Based on our investigation no analytical method has been reported for the simultaneous determination of nilotinib …